Tag: painful diabetic neuropathy

Education and collaboration key to continued advancement of painful diabetic neuropathy...

The neuromodulation space has proliferated significantly over the past few years, and one area in which this is most notable is with the expansion...

High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes

Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...

High responder rates, substantial pain relief and no explants among key...

Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...

Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...